Skip to main content
. 2022 Jun 21;6:41. doi: 10.1038/s41698-022-00289-1

Fig. 1. Patient demographic, pathology, and HDSCA3.0 workflow.

Fig. 1

a Patient’s diagnosis, pathology, disease progression, treatment history, and liquid biopsy timepoint. b HDSCA3.0 workflow including immunofluorescence staining and imaging, rare cell detection, CTC classification, molecular profiling, and downstream analyses.